SCINAI: 2023 In Review and 2024 Plans

Healthcare > Clinical Trials1/9/2024 3:00 PM

Go to Registration Page


CEO Amir Reichman will review Scinai’s 2023 accomplishments and discuss 2024 plans, including bringing Scinai’s anti-IL-17 VHH antibody (‘NanoAb’) innovative psoriasis treatment into clinical trials by the end of 2024.


Rate This Webinar

community rating (0 votes): 
Rate or Review This Webinar


Scinai Immunotherapeutics

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.